提示: 手机请竖屏浏览!

阿司匹林加重性呼吸系统疾病
Aspirin-Exacerbated Respiratory Disease


Andrew A. White ... 呼吸系统疾病 • 2018.09.13

水杨酸是在白柳树树皮的一种提取物中发现的,用于退热和止痛已有几千年的历史1。1897年,受雇于弗里德里希·拜耳公司(Friedrich Bayer and Company)的年轻化学家菲利克斯·霍夫曼(Felix Hoffmann)将水杨酸乙酰化,生成乙酰水杨酸。到1899年,拜耳为这种药物申请了专利,将其命名为“阿司匹林”,并开始在世界各地销售。阿司匹林的用量激增,当时阿司匹林被用于控制疼痛、发热、头痛、关节炎和其他疾病1。直至1922年,在Widal等人的一份病例报告中,才首次描述了阿司匹林加重性呼吸系统疾病2。一名具有基础呼吸系统疾病所有特征的女性志愿者使用阿司匹林进行口服激发,之后出现哮喘发作、大量鼻漏和荨麻疹。同样的反应发生在使用安替比林进行口服激发后,安替比林于1883年合成,是当时唯一的其他非甾体抗炎药(NSAID)。

1967年,美国一位不知晓1922年法国报告的免疫学家马克斯·萨姆特(Max Samter)认为,他发现了这种疾病并将其命名为“萨姆特三联征”(鼻息肉、哮喘和阿司匹林敏感)3。从那时起,出现了许多描述这种疾病的词(例如阿司匹林不耐受、阿司匹林特异反应性和阿司匹林诱发的哮喘)。在美国,阿司匹林加重性呼吸系统疾病(AERD)成为首选术语,这反映出人们不再认为这种疾病只发生在下呼吸道。虽然AERD在美国和世界其他许多国家是首选术语,但欧洲和中东的许多地区更喜欢NSAID加重性呼吸系统疾病。





作者信息

Andrew A. White, M.D., and Donald D. Stevenson, M.D.
From the Division of Allergy, Asthma, and Immunology, Scripps Clinic, San Diego, CA. Address reprint requests to Dr. Stevenson at the Scripps Clinic, Division of Allergy, Asthma, and Immunology, 3811 Valley Centre Dr., San Diego, CA 92130, or at dstevensonmd@gmail.com.

 

参考文献

1. Mann CC, Plummer ML. The aspirin wars: money, medicine and 100 years of rampant competition. Boston: Harvard Business School Press, 1991:22-27

2. Widal F, Abrami P, Lermoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-193.

3. Samter M, Beers RF Jr. Concerning the nature of intolerance to aspirin. J Allergy 1967;40:281-293.

4. Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2002;89:474-478.

5. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. Eur Respir J 2000;16:432-436.

6. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988;18:15-20.

7. Cardet JC, White AA, Barrett NA, et al. Alcohol-induced respiratory symptoms are common in patients with aspirin exacerbated respiratory disease. J Allergy Clin Immunol Pract 2014;2:208-213.

8. Kim JE, Kountakis SE. The prevalence of Samter’s triad in patients undergoing functional endoscopic sinus surgery. Ear Nose Throat J 2007;86:396-399.

9. Bochenek G, Kuschill-Dziurda J, Szafraniec K, Plutecka H, Szczeklik A, Nizankowska-Mogilnicka E. Certain subphenotypes of aspirin-exacerbated respiratory disease distinguished by latent class analysis. J Allergy Clin Immunol 2014;133(1):98-103.e1-6.

10. Lumry WR, Curd JG, Zeiger RS, Pleskow WW, Stevenson DD. Aspirin-sensitive rhinosinusitis: the clinical syndrome and effects of aspirin administration. J Allergy Clin Immunol 1983;71:580-587.

11. Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-975.

12. Mascia K, Borish L, Patrie J, Hunt J, Phillips CD, Steinke JW. Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2005;94:652-657.

13. Divekar R, Patel N, Jin J, et al. Symptom-based clustering in chronic rhinosinusitis relates to history of aspirin sensitivity and postsurgical outcomes. J Allergy Clin Immunol Pract 2015;3(6):934-940.e3.

14. Morales DR, Guthrie B, Lipworth BJ, Jackson C, Donnan PT, Santiago VH. NSAID-exacerbated respiratory disease: a meta-analysis evaluating prevalence, mean provocative dose of aspirin and increased asthma morbidity. Allergy 2015;70:828-835.

15. Fan Y, Feng S, Xia W, et al. Aspirin-exacerbated respiratory disease in China: a cohort investigation and literature review. Am J Rhinol Allergy 2012;26(1):e20-e22.

16. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000;23:290-296.

17. Dahlin A, Weiss ST. Genetic and epigenetic components of aspirin-exacerbated respiratory disease. Immunol Allergy Clin North Am 2016;36:765-789.

18. Laidlaw TM, Boyce JA. Aspirin-exacerbated respiratory disease — new prime suspects. N Engl J Med 2016;374:484-488.

19. Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153:572-575.

20. Vanselow NA, Smith JR. Bronchial asthma induced by indomethacin. Ann Intern Med 1967;66:568-572.

21. Samter M, Beers RF Jr. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-983.

22. Campobasso CP, Procacci R, Caligara M. Fatal adverse reaction to ketorolac tromethamine in asthmatic patient. Am J Forensic Med Pathol 2008;29:358-363.

23. Settipane RA, Stevenson DD. Cross sensitivity with acetaminophen in aspirin-sensitive subjects with asthma. J Allergy Clin Immunol 1989;84:26-33.

24. Szczeklik A, Nizankowska E, Dworski R. Choline magnesium trisalicylate in patients with aspirin-induced asthma. Eur Respir J 1990;3:535-539.

25. Stevenson DD, Hougham AJ, Schrank PJ, Goldlust MB, Wilson RR. Salsalate cross-sensitivity in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 1990;86:749-758.

26. Morales DR, Lipworth BJ, Guthrie B, Jackson C, Donnan PT, Santiago VH. Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: meta-analysis of controlled clinical trials. J Allergy Clin Immunol 2014;134:40-45.

27. Bavbek S, Dursun AB, Dursun E, Eryilmaz A, Misirligil Z. Safety of meloxicam in aspirin-hypersensitive patients with asthma and/or nasal polyps: a challenge-proven study. Int Arch Allergy Immunol 2007;142:64-69.

28. Dursun AB, Woessner KA, Simon RA, Karasoy D, Stevenson DD. Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis. Ann Allergy Asthma Immunol 2008;100:420-425.

29. Lee-Sarwar K, Johns C, Laidlaw TM, Cahill KN. Tolerance of daily low-dose aspirin does not preclude aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015;3:449-451.

30. Divekar R, Hagan J, Rank M, et al. Diagnostic utility of urinary LTE4 in asthma, allergic rhinitis, chronic rhinosinusitis, nasal polyps, and aspirin sensitivity. J Allergy Clin Immunol Pract 2016;4:665-670.

31. White A, Bigby T, Stevenson D. Intranasal ketorolac challenge for the diagnosis of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2006;97:190-195.

32. Nizankowska E, Bestyńska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-869.

33. Alonso-Llamazares A, Martinez-Cócera C, Domínguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy 2002;57:632-635.

34. Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol 2015;135(3):676-681.e1.

35. Weber RW, Hoffman M, Raine DA Jr, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-37.

36. Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy 1976;6:177-181.

37. Cahill KN, Johns CB, Cui J, et al. Automated identification of an aspirin-exacerbated respiratory disease cohort. J Allergy Clin Immunol 2017;139(3):819-825.e6.

38. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-235.

39. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67-69.

40. von Moltke J, Ji M, Liang HE, Locksley RM. Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit. Nature 2016;529:221-225.

41. Buchheit KM, Cahill KN, Katz HR, et al. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137(5):1566-1576.e5.

42. Liu T, Kanaoka Y, Barrett NA, et al. Aspirin-exacerbated respiratory disease involves a cysteinyl leukotriene-driven IL-33-mediated mast cell activation pathway. J Immunol 2015;195:3537-3545.

43. Arm JP, O’Hickey SP, Spur BW, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989;140:148-153.

44. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-846.

45. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-1029.

46. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-990.

47. Gauvreau GM, Parameswaran KN, Watson RM, O’Byrne PM. Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma. Am J Respir Crit Care Med 2001;164:1495-1500.

48. Lee TH, Austen KF, Corey EJ, Drazen JM. Leukotriene E4-induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulfidopeptide leukotriene receptors. Proc Natl Acad Sci U S A 1984;81:4922-4925.

49. Bankova LG, Lai J, Yoshimoto E, et al. Leukotriene E4 elicits respiratory epithelial cell mucin release through the G-protein-coupled receptor, GPR99. Proc Natl Acad Sci U S A 2016;113:6242-6247.

50. Kanaoka Y, Maekawa A, Austen KF. Identification of GPR99 protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013;288:10967-10972.

51. Cahill KN, Raby BA, Zhou X, et al. Impaired E prostanoid2 expression and resistance to prostaglandin E2 in nasal polyp fibroblasts from subjects with aspirin-exacerbated respiratory disease. Am J Respir Cell Mol Biol 2016;54:34-40.

52. Machado-Carvalho L, Martín M, Torres R, et al. Low E-prostanoid 2 receptor levels and deficient induction of the IL-1β/IL-1 type I receptor/COX-2 pathway: vicious circle in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2016;137(1):99-107.e7.

53. Steinke JW, Liu L, Huyett P, Negri J, Payne SC, Borish L. Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2013;132(4):856-865.e1.

54. Laidlaw TM, Kidder MS, Bhattacharyya N, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012;119:3790-3798.

55. Cahill KN, Bensko JC, Boyce JA, Laidlaw TM. Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2015;135:245-252.

56. Dahlén B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-1194.

57. Adelman J, McLean C, Shaigany K, Krouse JH. The role of surgery in management of Samter’s triad: a systematic review. Otolaryngol Head Neck Surg 2016;155:220-237.

58. Rudmik L, Soler ZM, Hopkins C, et al. Defining appropriateness criteria for endoscopic sinus surgery during management of uncomplicated adult chronic rhinosinusitis: a RAND/UCLA appropriateness study. Rhinology 2016;54:117-128.

59. Morrissey DK, Bassiouni A, Psaltis AJ, Naidoo Y, Wormald PJ. Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. Int Forum Allergy Rhinol 2016;6:820-825.

60. Adappa ND, Ranasinghe VJ, Trope M, et al. Outcomes after complete endoscopic sinus surgery and aspirin desensitization in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol 2018;8:49-53.

61. Levy JM, Rudmik L, Peters AT, Wise SK, Rotenberg BW, Smith TL. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations. Int Forum Allergy Rhinol 2016;6:1273-1283.

62. Zeiss CR, Lockey RF. Refractory period to aspirin in a patient with aspirin-induced asthma. J Allergy Clin Immunol 1976;57:440-448.

63. Bianco S, Robuschi M, Petrigni G, et al. Aspirin-induced tolerance in aspirin-induced asthma detected by a new challenge technique. IRCS J Med Sci 1977;5:129-130.

64. Stevenson DD, Simon RA, Mathison DA. Aspirin-sensitive asthma: tolerance to aspirin after positive oral aspirin challenges. J Allergy Clin Immunol 1980;66:82-88.

65. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: a prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 2008;63:1228-1234.

66. Świerczyńska-Krępa M, Sanak M, Bochenek G, et al. Aspirin desensitization in patients with aspirin-induced and aspirin-tolerant asthma: a double-blind study. J Allergy Clin Immunol 2014;134:883-890.

67. Esmaeilzadeh H, Nabavi M, Aryan Z, et al. Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: a randomized double-blind placebo-controlled trial. Clin Immunol 2015;160:349-357.

68. Kowalski ML, Grzelewska-Rzymowska I, Szmidt M, Rozniecki J. Clinical efficacy of aspirin in “desensitised” aspirin-sensitive asthmatics. Eur J Respir Dis 1986;69:219-225.

69. Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg 2014;151:575-581.

70. Fruth K, Pogorzelski B, Schmidtmann I, et al. Low-dose aspirin desensitization in individuals with aspirin-exacerbated respiratory disease. Allergy 2013;68:659-665.

71. Stevenson DD, Pleskow WW, Simon RA, et al. Aspirin-sensitive rhinosinusitis asthma: a double-blind crossover study of treatment with aspirin. J Allergy Clin Immunol 1984;73:500-507.

72. Sweet JM, Stevenson DD, Simon RA, Mathison DA. Long-term effects of aspirin desensitization — treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990;85:59-65.

73. Berges-Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003;111:180-186.

74. Sousa AR, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002;347:1493-1499.

75. Nasser SM, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995;151:1326-1330.

76. Steinke JW, Culp JA, Kropf E, Borish L. Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: possible role in therapeutic benefit associated with aspirin desensitization. J Allergy Clin Immunol 2009;124(4):724-30.e4.

77. Katial RK, Strand M, Prasertsuntarasai T, Leung R, Zheng W, Alam R. The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. J Allergy Clin Immunol 2010;126:738-744.

78. Stevenson DD, Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 2006;118:801-804.

79. Shaker M, Lobb A, Jenkins P, et al. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2008;121:81-87.

80. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996;98:751-758.

81. Lee JY, Simon RA, Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2007;119:157-164.

82. Waldram J, Walters K, Simon R, Woessner K, Waalen J, White A. Safety and outcomes of aspirin desensitization for aspirin-exacerbated respiratory disease: a single-center study. J Allergy Clin Immunol 2018;141:250-256.

83. White A, Ludington E, Mehra P, Stevenson DD, Simon RA. Effect of leukotriene modifier drugs on the safety of oral aspirin challenges. Ann Allergy Asthma Immunol 2006;97:688-693.

84. Chen JR, Buchmiller BL, Khan DA. An hourly dose-escalation desensitization protocol for aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 2015;3(6):926-931.e1.

85. Lee RU, White AA, Ding D, et al. Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease. Ann Allergy Asthma Immunol 2010;105:130-135.

86. Macy E, Bernstein JA, Castells MC, et al. Aspirin challenge and desensitization for aspirin-exacerbated respiratory disease: a practice paper. Ann Allergy Asthma Immunol 2007;98:172-174.

服务条款 | 隐私政策 | 联系我们